Wide Ranks

IRTC

iRhythm Technologies, Inc.

89.02

Top Statistics
Market Cap 2 B Forward PE -51.16 Revenue Growth 18.40 %
Current Ratio 6.27 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -26.90 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -33.09 Enterprise / Revenue 5.36 Price To Sales Trailing12 Months 4.98
Profitability
Profit Margins -26.90 % Operating Margins -6.94 %
Balance Sheet
Total Cash 522 M Total Cash Per Share 16.68 Total Debt 735 M
Total Debt To Equity 1024.67 Current Ratio 6.27 Book Value Per Share 2.29
All Measures
Short Ratio 346.00 % Message Board Id finmb_34159879 Shares Short Prior Month 2 M
Return On Equity -1.03 City San Francisco Uuid ff7fb9c7-9fc9-30be-9651-f10e31d8b26f
Previous Close 82.45 First Trade Date Epoch Utc 1 B Book Value 2.29
Beta 1.23 Total Debt 735 M Volume 555671
Price To Book 38.81 Fifty Two Week Low 55.92 Total Cash Per Share 16.68
Total Revenue 560 M Shares Short Previous Month Date 1 B Target Median Price 96.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -6.94 %
Target Mean Price 98.27 Net Income To Common -150655008 Short Percent Of Float 0.0775
Implied Shares Outstanding 31 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 477920 Average Volume10days 477920 Total Cash 522 M
Next Fiscal Year End 1 B Revenue Per Share 18.05 Held Percent Insiders 0.0079
Ebitda Margins -16.19 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 82.45 Target Low Price 79.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 73.51 Open 83.13
Free Cashflow -43469752 State CA Dividend Yield 0.00 %
Return On Assets -0.0893 Time Zone Short Name EST Trailing Eps -4.85
Day Low 82.55 Address1 699 8th Street Shares Outstanding 31 M
Price Hint 2 Target High Price 125.00 Website https://www.irhythmtech.com
52 Week Change 0.0439 Average Volume 589643 Forward Eps -1.84
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 598.80 %
Is_sp_500 False Regular Market Day High 89.10 Profit Margins -26.90 %
Debt To Equity 1024.67 Fifty Two Week High 124.11 Day High 89.10
Shares Short 2 M Regular Market Open 83.13 Industry Key medical-devices
Earnings Growth 0.00 % Enterprise To Revenue 5.36 Revenue Growth 18.40 %
Shares Percent Shares Out 0.0771 Operating Cashflow -31814000 Currency USD
Time Zone Full Name America/New_York Market Cap 2 B Is_nasdaq_100 False
Zip 94103 Quote Type EQUITY Industry Medical Devices
Long Name iRhythm Technologies, Inc. Regular Market Day Low 82.55 Held Percent Institutions 1.15
Current Price 89.02 Address2 Suite 600 Enterprise To Ebitda -33.09
Financial Currency USD Current Ratio 6.27 Gross Margins 67.83 %
Industry Disp Medical Devices Number Of Analyst Opinions 11 Country United States
Float Shares 30 M Two Hundred Day Average 90.34 Enterprise Value 2 B
Price To Sales Trailing12 Months 4.98 Forward PE -51.16 Regular Market Volume 555671
Ebitda -90648000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.

It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.

The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period.

It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products.

The company was incorporated in 2006 and is headquartered in San Francisco, California.